Description
Zevra Therapeutics Sparks Buyout Buzz: Why Commave Therapeutics Is Eyeing Its SDX Portfolio!
Zevra Therapeutics has recently attracted acquisition interest around its SDX portfolio, with reports indicating that Commave Therapeutics is evaluating the asset as a potential strategic purchase. The SDX portfolio, which includes products such as AZSTARYS and related intellectual property and royalty streams, represents a differentiated set of assets within Zevra’s broader rare disease platform. While Zevra has increasingly focused its corporate strategy on rare diseases—highlighted by the commercial launch of MIPLYFFA for Niemann-Pick disease type C (NPC) and the development of celiprolol for vascular Ehlers-Danlos syndrome—the SDX assets remain an attractive opportunity for companies seeking exposure to neurology and central nervous system therapeutics. Commave Therapeutics’ interest appears to stem from the potential to leverage the portfolio’s established commercial infrastructure, intellectual property protections, and existing royalty streams. With Zevra reporting $106.5 million in 2025 revenue and maintaining a strong balance sheet with $238.
